Pace Logo

News Category: Life Sciences

Pace® Life Sciences Acquires New Jersey Laboratory from Curia

Former Whitehouse Analytical Laboratory is Now Part of the Pace® Laboratory Network Minneapolis, MN [March 14, 2024] Pace® Life Sciences, LLC, a contract development, and manufacturing organization (CDMO), announced today that it has acquired the Lebanon, New Jersey laboratory facility (formerly Whitehouse Analytical Laboratories) from Curia, a global contract research, development, and manufacturing (CDMO) company. …

Pace® Life Sciences Acquires New Jersey Laboratory from Curia Read More »

Pace® Life Sciences Appoints Dawn Von Rohr as Division President

Von Rohr brings over 25 years of experience to company  Pace® Life Sciences, a full-service contract development and manufacturing organization (CDMO) and a Division of Pace®, a Science and Technology Company, announced today that Dawn Von Rohr has been named Division President. Von Rohr will be responsible for driving growth and continued innovations within the Pace® …

Pace® Life Sciences Appoints Dawn Von Rohr as Division President Read More »

Crucial Role of Testing Labs in Pipeline Emergency Response

By John Gerken, Vice President of Corporate Accounts and Specialty Analytical Services, Pace  (P&GJ) — Emergency situations, like explosions due to pipeline ruptures, often happen instantly and without warning. Pipeline managers know about the risks that come with the job, but the aftereffects of pipeline ruptures and leaks are often secondary to protecting human life.  …

Crucial Role of Testing Labs in Pipeline Emergency Response Read More »

Pace® Life Sciences Adds Liquid Capsule Filling Technology

Pace® Life Sciences continues to make investments to broaden their comprehensive suite of oral solid dose development offerings. ANN ARBOR, Mich., December 19, 2023 (Newswire) – Pace® Life Sciences, a full-service contract development and manufacturing organization (CDMO) and a Division of Pace®, a Science and Technology Company, adds liquid capsule filling technology to their comprehensive suite of …

Pace® Life Sciences Adds Liquid Capsule Filling Technology Read More »

Delnova Unveils Partnership With Pace® Life Sciences To Boost Capabilities

DelNova’s partnership will enable clinical development of its lead candidate ReViVox® for the rescue of undesirable outcomes which may arise from a botulinum neurotoxin (BoNT) treatment such as Botox®. Pace® Life Sciences provides a full suite of contract CMC development, clinical trials materials manufacturing, and regulatory compliance, services to the biopharmaceutical industries. SAN DIEGO, Oct. …

Delnova Unveils Partnership With Pace® Life Sciences To Boost Capabilities Read More »

ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy

Pace ® is happy to share news from our client, ReveraGen BioPharma Inc., on a significant accomplishment! ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy. Pace® Ann Arbor (legacy Velesco Pharmaceutical Services) contributed significantly to this success. Velesco Pharma (now Pace®) performed the drug product clinical formulation development and all drug …

ReveraGen Completes NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy Read More »

Pace® Life Sciences Acquires Biopharma Global, Expanding FDA Regulatory Affairs Strategy and Consulting Capabilities to the Biotechnology and Pharmaceutical Markets

Acquisition allows Pace® to provide full-service regulatory strategy and consulting services to advance FDA submissions across a wide range of therapeutic classes. Minneapolis, MN, September 1, 2022 – Pace® Life Sciences, LLC, a full-service contract development and manufacturing organization (CDMO) and subsidiary of Pace®, ascience and technology company, announced today that it has acquired Biopharma …

Pace® Life Sciences Acquires Biopharma Global, Expanding FDA Regulatory Affairs Strategy and Consulting Capabilities to the Biotechnology and Pharmaceutical Markets Read More »

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave BioPharma Chooses Pace® Life Sciences as CDMO Partner. BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) — First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today the selection of an enhanced enteric microgranule …

First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation Read More »